TrialThe Lancet. Respiratory medicine2019

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.

Conor D Tweed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.